AOP Orphan reports full validity of arbitral award against PharmaEssentia 25 marzo, 2021 Vienna (pts027/25.03.2021/13:50) – Today the Higher Regional Court of Frankfurt declared Leer más »
BESREMi® (Ropeginterferon alfa-2b) deemed safe and efficacious by the US FDA 15 marzo, 2021 Vienna (pts022/15.03.2021/13:45) – The US Food & Drug Administration (FDA) issued Leer más »
European ICU Drug Supports Patients in Canada 1 febrero, 2021 Vienna (pts018/01.02.2021/12:25) – Development and clinical data from the European Healthcare Leer más »
AOP Orphan: PAH treatment for patients in Argentina 26 enero, 2021 Vienna, Austria (pts026/26.01.2021/12:55) – The Austrian pharmaceutical company AOP Orphan Leer más »
AOP Orphan announces 5-year results on BESREMi® (Ropeginterferon alfa-2b) in PV at the ASH Annual Meeting 2020 6 diciembre, 2020 Vienna, Austria (pts001/07.12.2020/00:00) – Ropeginterferon alfa-2b showed clear advantages in efficacy Leer más »